JAGX, GRML, VKTX Soar on FDA News, Biotech, and Minerals

Font: Financial Modeling Prep  • Sep 22, 2026

Market Movers: Jaguar Health, Greenland Mines, and Viking Therapeutics Lead Gains

• Jaguar Health (NASDAQ: JAGX) surged after receiving FDA fee waivers for Mytesi and Canalevia-CA1.
• Greenland Mines (NASDAQ: GRML) continued to rally on Greenland-related strategic metals interest.
• Viking Therapeutics (NASDAQ: VKTX) jumped after positive weight-loss drug data.

Several high-volume stocks posted major gains as investors reacted to regulatory updates, biotech data, and geopolitical interest in critical minerals.

Jaguar Health (NASDAQ: JAGX) surged about 1,156.6% to $34.46 after the FDA granted fee waivers for Mytesi and Canalevia-CA1 for fiscal 2027. The move was extremely volatile, with heavy trading volume.

Greenland Mines (NASDAQ: GRML) rose 49.7% to $14.15, continuing its rally after recent U.S.-Greenland security developments increased investor interest in Greenland-linked mineral assets.

Viking Therapeutics (NASDAQ: VKTX) gained 35.6% to $40.85 after positive data for its obesity drug candidate VK2735, which showed strong weight-loss maintenance results.

Butterfly Network (NYSE: BFLY) advanced 22.1% to $9.93, while Maze Therapeutics (NASDAQ: MAZE) climbed 26.8% to $28.38. Maze’s move came despite a recent insider-sale filing, which remains a caution point for investors.

Overall, the day’s biggest gainers were driven by FDA-related news, biotech trial momentum, and critical-minerals speculation.